MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma

Oncology Reports

Volumn 34, Issue 1, 2015, Pages 175-182

  Xu, Hui ^a,b   Hu, Yan Wei ^a   Zhao, Jia Yi ^a   Hu, Xiu Mei ^a   Li, Shu Fen ^a   Wang, Yan Chao ^a   Gao, Ji Juan ^a   Sha, Yan Hua ^a   Kang, Chun Min ^a   Lin, Li ^a   Huang, Chuan ^a   Zhao, Jing Jing ^a   Zheng, Lei ^a   Wang, Qian ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Department of Gastroenterology Qingyuan Hospital of Traditional Chinese Medicine   (China)

Author keywords

Hepatocellular carcinoma; Migration; miR 195 5p; PHF19; Proliferation

Indexed keywords

MICRORNA; MICRORNA 195 5P; PHD FINGER PROTEIN 19; POLYCOMB REPRESSIVE COMPLEX 2; UNCLASSIFIED DRUG; MIRN195 MICRORNA, HUMAN; NUCLEAR PROTEIN; PHF19 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; ONCOGENE; PHF19 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL MOTION; DRUG SCREENING; GENETICS; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; LIVER NEOPLASMS; MICE; MICRORNAS; NUCLEAR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930028749     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3957     Document Type: Article

References (27)

1. Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, et al: Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 60: 872-883, 2014.
2. Jain S, Singhal S, Lee P and Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2: 105-118, 2010.
3. Nault JC and Zucman-Rossi J: Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31: 173-187, 2011.
4. Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P, Song F, Zheng H, Yu J, Song T, et al: Regulatory miR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology 61: 574-584, 2015.
5. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52, 2007.
6. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, et al: An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147: 1233-1247, 2011.
7. Wang S, Robertson GP and Zhu J: A novel human homologue of Drosophila polycomb like gene is up-regulated in multiple cancers. Gene 343: 69-78, 2004.
8. Ballaré C, Lange M, Lapinaite A, Martin GM, Morey L, Pascual G, Liefke R, Simon B, Shi Y, Gozani O, et al: Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat Struct Mol Biol 19: 1257-1265, 2012.
9. Ghislin S, Deshayes F, Middendorp S, Boggetto N and Alcaide-Loridan C: PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 11: 1634-1645, 2012.
10. Li G, Warden C, Zou Z, Neman J, Krueger JS, Jain A, Jandial R and Chen M: Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One 8: e80970, 2013.
11. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
12. Laloo B, Simon D, Veillat V, Lauzel D, Guyonnet-Duperat V, Moreau-Gaudry F, Sagliocco F and Grosset C: Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method. Mol Cell Proteomics 8: 1777-1788, 2009.
13. Breving K and Esquela-Kerscher A: The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42: 1316-1329, 2010.
14. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480, 2009.
15. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA and Martens JW: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105: 13021-13026, 2008.
16. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA and Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 68: 5795-5802, 2008.
17. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM: microRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50: 113-121, 2009.
18. Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C and Lui WO: The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 18: 643-655, 2011.
19. Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, Zhou H and Qu LH: MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol 14: 278-287, 2012.
20. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17: 1722-1730, 2011.
21. Jin Q, Marsh J, Cornetta K and Alkhatib G: Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol 89: 2611-2621, 2008.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
23. Margueron R and Reinberg D: The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349, 2011.
24. Schuettengruber B and Cavalli G: Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development 136: 3531-3542, 2009.
25. Simon JA and Kingston RE: Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10: 697-708, 2009.
26. Brien GL, Gambero G, O'Connell DJ, Jerman E, Turner SA, Egan CM, Dunne EJ, Jurgens MC, Wynne K, Piao L, et al: Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nat Struct Mol Biol 19: 1273-1281, 2012.
27. Callahan R, Mudunur U, Bargo S, Raafat A, McCurdy D, Boulanger C, Lowther W, Stephens R, Luke BT, Stewart C, et al: Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors. Oncotarget 3: 1320-1334, 2012.